Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan

Renalys Pharma, Inc. announced that it has submitted an Investigational New Drug Application for sparsentan to the Pharmaceuticals and Medical Devices Agency for a Phase III clinical trial in Japan.